CClinicalTrials.gg
CompletedNCT06681961Updated Nov 12, 2024

Effects of a Squatting With Hip Adduction in Patients With Patellofemoral Pain Syndrome

An interventional study of squatting with hip adduction (SQU-HA) group in PFPS, sponsored by China Medical University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 11 months after the study started (first participant enrolled Nov 2017, registered Nov 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

An imbalance in the activation and onset time of the vastus medialis oblique (VMO) and vastus lateralis (VL) muscles may be one of the primary causes of PFPS. Several studies have discussed various exercise methods believed to selectively contract the (VMO) muscle for treating patellofemoral pain syndrome. VMO activity is higher during static closed-chain tasks combined with hip adduction, indicating that performing hip adduction exercises may selectively strengthen the VMO muscle.

Read the detailed description

Patellofemoral pain syndrome (PFPS) poses challenges in motor control and pain management, especially regarding balanced muscle activation of the vastus medialis oblique (VMO) and vastus lateralis (VL). This study introduces a home-based PFPS rehabilitation approach involving a squat exercise program with hip adduction, examining its effects on motor control and clinical outcomes. Thirty PFPS participants were randomly assigned to conventional squatting (SQU) or squatting with hip adduction (SQU-HA) groups. Participants performed exercises five days a week for 8 weeks, with pre- and post-assessments capturing clinical measures and motor control indicators using electromyography (EMG). This home-based program, integrating hip adduction into squats, enhances motor control, reduces knee stress, and improves daily function, ensuring continued care post-pandemic.

02

Conditions studied

  • PFPS

Keywords

  • Patellofemoral pain syndrome
  • Vastus medialis obliquus
  • Squatting
  • Hip adduction
03

In context

Patellofemoral Pain Syndrome

295 studies on the registry are indexed under Patellofemoral Pain Syndrome; 75 are open to participants now.

This study's enrollment of 30 is below the median of 45 across 242 interventional studies indexed under Patellofemoral Pain Syndrome.

Browse Patellofemoral Pain Syndrome studies →

Lead sponsor

China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 20-50 years.
  • Pain around the patella at least two of the following activities¬-standing up after prolonged sitting, going up and down the stairs, running, jumping, squatting, kneeling, and high-angle knee flexion for a long time.
  • Knee joint pain for ≥3 months.
  • Pain level of ≥ 30 mm on a 100-mm visual analog scale (VAS).

Exclusion criteria

Exclusion Criteria:

  • Had a history of patellar subluxation, dislocation, or knee surgery.
  • Had central or peripheral neurological pathology.
  • Had an obvious knee joint deformity or lower extremity malalignment.
  • Experienced severe knee joint pain (VAS) score > 80 mm), or received nonsteroidal anti-inflammatory drugs, injections, or physical therapy within the past 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    squatting with hip adduction (SQU-HA) group

    The participants stood equally on both legs on the floor with their feet shoulder-width apart and angled outward at 20°-30°. After a warm-up, the participants performed 45° squats with squeezing a Swiss ball of 18-cm diameter at a slow speed of 2 s for flexion and extension from the standing posture by using a commercial metronome. The squatting with knee flexion from 0° to 45° was the safest for people with PFPS.

    Other: squatting with hip adduction (SQU-HA) group

  • Other
    squatting (SQU) group

    The participants stood equally on both legs on the floor with their feet shoulder-width apart and angled outward at 20°-30°. After a warm-up, the participants performed 45° squats at a slow speed of 2 s for flexion and extension from the standing posture by using a commercial metronome. The squatting with knee flexion from 0° to 45° was the safest for people with PFPS.

    Other: squatting with hip adduction (SQU-HA) group

Interventions

  • Othersquatting with hip adduction (SQU-HA) group

    The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.

    Also known as: squatting (SQU) group

06

What researchers measure

Primary outcomes

  1. Amplitudes of muscle activation (unit: %MVC)

    represented the mean RMSs for each muscle which was normalized by the maximal voluntary contractions (MVC).

    Time frame: pre-intervention and after 8-week intervention

  2. VMO/VL ratio

    represents the amplitude ratio of VMO relative to VL.

    Time frame: pre-intervention and after 8-week intervention

  3. Onset time (unit: msec)

    at 200 ms before the beginning of the trial, as the baseline, the onset of EMG activation was identified as the point at which the EMG amplitude was more than three standard deviations from the baseline level for at least 25 ms.

    Time frame: pre-intervention and after 8-week intervention

  4. VMO - VL (unit: msec)

    represented the onset time differences of VMO relative to VL, with a positive (negative) value indicating a delayed (early) onset time of VMO relative to VL.

    Time frame: pre-intervention and after 8-week intervention

  5. Q angle (unit: degree)

    The angle was calculated with the intersection formed by two lines crossing the center of the patella. The first line went from the ASIS to the center of the patella and the second from the anterior tuberosity of the tibia to the center of the patella.

    Time frame: pre-intervention and after 8-week intervention

  6. The visual analogue scale (VAS) (unit: mm)

    VAS was used to assess pain severity. The participants were asked to mark their pain levels on a 100-mm ruler (ranging from 0 = "no pain" to 100 = "unbearable pain") before and after the exercise program.

    Time frame: pre-intervention and after 8-week intervention

  7. patellofemoral pain severity scale (PSS) (unit: score)

    PSS was used to measure PFPS associated with functional activities over the past week. The scale comprises 10 items, including climbing/descending stairs, squatting, walking, jogging, running/sprinting, participating in a sport, sitting with knees bent (for 20 min), kneeling, resting, and following an activity. The maximum score was 100 points. The participants rated their pain on a 100-mm VAS, ranging from 0 = "no pain" to 100 = "unbearable pain".

    Time frame: pre-intervention and after 8-week intervention

07

Study locations

1 site
  • China Medical University
    Taichung, 406040, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06681961
Lead sponsor
China Medical University Hospital
Responsible party
Wei-Hsien Hong (China Medical University, China Medical University Hospital) — Principal investigator
First posted
Nov 12, 2024
Start date
Nov 27, 2017
Primary completion
Nov 30, 2018
Completion
Jan 5, 2019
Last update
Nov 12, 2024

Study contacts

Wei-Hsien Hong, PhD
principal investigator · China Medical University, Taiwan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion